🟢 Strong Evidence
Researchers have developed a precision CAR T cell therapy that selectively targets and depletes disease-driving mutant calreticulin cells in myelofibrosis, according to a study published in Science Translational Medicine in July 2026. The therapy demonstrated selective depletion of mutant cells in both xenotransplant models and human organoid systems, offering a potentially transformative approach to treating this hematologic malignancy with reduced off-target effects.
Key takeaways
- CAR T cells engineered to recognize mutant calreticulin successfully depleted disease-driving cells in preclinical models
- The therapy showed selective targeting with minimal impact on normal hematopoietic cells in organoid systems
- This approach represents a shift toward genotype-specific immunotherapy, potentially reducing toxicity seen in broader immune interventions
- Human organoid validation strengthens the translational pathway toward clinical trials in myelofibrosis patients
Study at a Glance
| Source | Science Translational Medicine |
| Study type | Preclinical translational research (xenotransplants + organoid models) |
| Model systems | Mouse xenografts and human myelofibrosis organoids |
| Target | Mutant calreticulin (CALR)-expressing cells |
| Publication date | July 2026 (Volume 18, Issue 856) |
CAR T Cell Therapy Development: From Mechanism to Clinical Translation
Progression of genotype-specific immunotherapy across preclinical model systems, 2026
Source: Science Translational Medicine, July 2026 | Georgian Medical Journal News
Calreticulin mutations as a disease-driver in myelofibrosis
Myelofibrosis is a myeloproliferative neoplasm characterized by bone marrow fibrosis, extramedullary hematopoiesis, and constitutional symptoms. Approximately 25–30% of myelofibrosis patients harbor somatic mutations in CALR (calreticulin), a gene encoding an endoplasmic reticulum chaperone protein. These mutations are clonally dominant and drive disease pathogenesis through altered thrombopoietin signaling.
Previous therapeutic approaches in myelofibrosis have focused on JAK inhibitors (such as ruxolitinib), which target downstream inflammatory signaling but do not eliminate the mutant clone. The new CAR T cell approach published in Science Translational Medicine offers a mechanistically distinct strategy: direct targeting and depletion of the cell population expressing the disease-causing mutation itself, potentially achieving deeper disease control at the clonal level.
Engineering CAR T cells to recognize mutant calreticulin
The research team engineered CAR T cells to express chimeric antigen receptors (CARs) specific to epitopes derived from mutant calreticulin. In preclinical testing using xenotransplant models—where human myelofibrosis cells are engrafted into immunocompromised mice—the CAR T cells successfully infiltrated tumors and depleted CALR-mutant cells. Importantly, the cells demonstrated specificity for the mutant protein, minimizing recognition of wild-type calreticulin expressed on normal cells.
To bridge the translational gap toward human application, the research team further validated the approach in human myelofibrosis organoid models derived from patient samples. These three-dimensional organoid systems better recapitulate the microenvironment and cellular complexity of bone marrow compared to traditional cell lines, providing a more physiologically relevant testing ground for off-target toxicity assessment.
Organoid validation strengthens the translational pathway
The organoid experiments yielded a critical finding for clinical translation: CAR T cells selectively depleted CALR-mutant cells while largely sparing normal hematopoietic stem and progenitor cells (HSPCs) in the same tissue. This selective targeting is essential because destruction of normal bone marrow cells would lead to severe cytopenias and transplant-related toxicity—a major limitation of broad-based immunotherapies.
According to the Science Translational Medicine study, the organoid model also allowed researchers to assess CAR T cell expansion dynamics, cytokine production, and persistence in a human-relevant context. These parameters are critical determinants of CAR T therapy efficacy and safety in subsequent clinical trials. The successful translation from xenograft to organoid provides confidence that the approach has sufficient selectivity and potency to warrant human investigation.
This work aligns with broader trends in cellular immunotherapy toward genotype-specific targeting, moving beyond tissue-of-origin or stage-based classification toward mutation-driven precision medicine.
Implications for myelofibrosis treatment and precision oncology
Myelofibrosis remains incurable with current standard therapies, and median survival ranges from 3–6 years depending on risk stratification. CAR T cell therapy offers a fundamentally different mechanism—clonal elimination rather than symptom suppression. If clinical efficacy is demonstrated, this approach could extend survival and quality of life for CALR-mutant patients, potentially extending the therapeutic window when combined with existing JAK inhibitors or transplantation strategies.
Beyond myelofibrosis, the success of CAR T targeting mutant calreticulin may encourage similar mutation-specific CAR T development for other driver mutations in hematologic and solid malignancies. The field of CAR T therapy has matured significantly since the first US FDA approvals in 2017 for B-cell lymphomas, and extension to rare genetic drivers represents a logical next phase in precision immunotherapy.
CAR T cells engineered to target mutant calreticulin selectively depleted disease-driving cells in xenograft and human organoid models of myelofibrosis while sparing normal hematopoietic cells, demonstrating the feasibility of genotype-specific immunotherapy and a potential new treatment avenue for this incurable myeloproliferative neoplasm.
— Research team, Science Translational Medicine, July 2026
What this means
Frequently asked questions
What percentage of myelofibrosis patients have CALR mutations?
Approximately 25–30% of primary myelofibrosis patients carry somatic CALR mutations, making them eligible candidates for this CAR T approach once it enters clinical trials. The remaining patients carry JAK2 or MPL mutations or have triple-negative disease, necessitating alternative immunotherapy designs.
How does CAR T calreticulin therapy differ from existing myelofibrosis treatments?
Current standard therapy (JAK inhibitors like ruxolitinib) suppresses inflammatory signaling but does not eliminate the mutant clone, so disease progression often occurs. CAR T therapy aims at direct clonal elimination by targeting the mutant calreticulin protein itself, potentially achieving longer remissions and possibly cure, though this remains to be proven in human trials.
Why were human organoids necessary for validating this therapy?
Organoid models better replicate the complexity of bone marrow microenvironment than cell lines or animal xenografts alone. They allowed researchers to confirm that CAR T cells could selectively deplete CALR-mutant cells while sparing normal hematopoietic precursors in a human-relevant system, reducing the risk of severe toxicity in future clinical trials.
The successful preclinical validation of CAR T calreticulin therapy marks an important milestone in precision hematologic oncology. While the transition from organoid to human efficacy is not guaranteed, the selective depletion observed in these models provides a rational foundation for Investigational New Drug (IND) applications and phase 1 trials. The next 24–36 months will be critical for determining whether this mutation-specific approach translates into clinical benefit for patients with CALR-mutant myelofibrosis. In parallel, researchers should investigate whether similar CAR T strategies can be engineered against other myelofibrosis driver mutations (JAK2, MPL) to broaden therapeutic reach across all myelofibrosis genotypes, working toward a comprehensive precision medicine framework for this serious blood disorder.
Source: CAR T cell therapy selectively depletes disease-driving mutant calreticulin cells in xenotransplants and human organoid models of myelofibrosis, Science Translational Medicine, July 2026
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Editorial standards. This article was produced under the GMJ News editorial process, with oversight by the GMJ Editorial Board. Our editorial process. Spotted an error? Contact the editorial team.
